IRCT20200523047550N1 IRCT 2020-06-06 Tehran University of Medical Sciences Effect of Umifenovir in treatment of covid-19 Evaluating effectiveness and safety of Umifenovir in the treatment (COVID-19)infection In patients referred to Tehran Imam Khomeini Hospital Complex 2020-04-20 anticipated 50 Complete https://irct.ir/trial/48495 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 3 covid 19. Intervention 1: Intervention group: Patients with probable or definitive diagnosis of covid 19 and have risk factor who have been treated with hydroxychloroquine also Received 200 mg arbidol capsule every 8 hours for 7 days. The company of the pharmaceutical is the Pharmstandard. Intervention 2: Control group: Patients with a probable or definitive diagnosis of covid 19 and a risk factor have been treated with hydroxychloroquine, on the first day, they were given 400 mg every 12 hours and then 200 mg every 12 hours for 7 days. Yes - There is a plan to make this available What will be shared: Objectives of the research, Research Design, Results When: 6 months after the publication of the results To whom: Physicians, researchers working in academic and scientific institutions Conditions: Use in research Where to obtain: My Email How to obtain: Name and surname, medical system number, position, university name, email Comments: